Used primarily in the treatment of non-small cell lung cancer (NSCLC) that is driven by abnormalities in the anaplastic lymphoma kinase (ALK) gene. It functions as a potent and selective ALK inhibitor, helping to block the signals that promote tumor growth. Ensartinib hydrochloride is especially effective against both wild-type ALK and various resistant mutants, including the common G1202R mutation, making it valuable in patients who have progressed on earlier ALK-targeted therapies. It is administered orally and has shown strong central nervous system penetration, which supports its use in patients with brain metastases. Clinical development has focused on its efficacy, safety, and potential as a first-line or later-line treatment option in ALK-positive NSCLC.